SAM
PCRX icon

Silvercrest Asset Management’s Pacira BioSciences PCRX Stock Holding History

Silvercrest Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-122,854
Closed -$4.92M – 855
2023
Q2 		$4.92M Buy
122,854
+18,596
+18% +$769K 0.04% 372
2023
Q1 		$4.25M Sell
104,258
-113
-0.1% -$4.5K 0.03% 377
2022
Q4 		$4.03M Sell
104,371
-171,080
-62% -$8.32M 0.03% 373
2022
Q3 		$14.7M Sell
275,451
-14,859
-5% -$826K 0.12% 186
2022
Q2 		$16.9M Sell
290,310
-7,926
-3% -$519K 0.13% 184
2022
Q1 		$22.8M Sell
298,236
-56,370
-16% -$3.76M 0.15% 173
2021
Q4 		$21.3M Buy
354,606
+78,559
+28% +$4.33M 0.14% 172
2021
Q3 		$15.5M Sell
276,047
-16,509
-6% -$951K 0.1% 203
2021
Q2 		$17.8M Sell
292,556
-20,288
-6% -$1.28M 0.12% 198
2021
Q1 		$21.9M Sell
312,844
-108,123
-26% -$7.72M 0.15% 174
2020
Q4 		$25.2M Buy
420,967
+21,648
+5% +$1.27M 0.18% 148
2020
Q3 		$24M Buy
399,319
+200,871
+101% +$11.7M 0.21% 134
2020
Q2 		$10.4M Sell
198,448
-3,533
-2% -$148K 0.09% 206
2020
Q1 		$6.77M Buy
201,981
+24,783
+14% +$1.03M 0.07% 232
2019
Q4 		$8.03M Sell
177,198
-7,522
-4% -$319K 0.06% 257
2019
Q3 		$7.03M Buy
+184,720
New +$7.37M 0.06% 260

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Silvercrest Asset Management's PCRX Position: Q3 2023 in Review

Silvercrest Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 122,854 shares — an estimated $4.92M sold.

Silvercrest Asset Management first reported a position in PCRX in Q3 2019 and held it in 16 quarters. The position peaked at $25.2M in Q4 2020. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Silvercrest Asset Management reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Silvercrest Asset Management sold 122,854 Pacira BioSciences shares in Q3 2023, an estimated $4.92M.
  • Silvercrest Asset Management first reported a position in Pacira BioSciences in Q3 2019 and held it in 16 quarters.
  • Silvercrest Asset Management's Pacira BioSciences position peaked at $25.2M in Q4 2020.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Silvercrest Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.